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Tumourigenesis is initiated by various factors and its progression is also affected by 
numerous elements. In 1980, Little and Kennedy performed malignant cell 
transformation experiment using x-irradiation to study the initiation and progression 
of tumourigenesis. Reproducing tumourigenesis in vitro is challenging, yet, they 
accomplished the task and almost 40 years later, I am here to elucidate unsolved 
questions beneath that experiment. Firstly, genomic alterations were investigated 
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using whole-genome sequencing. Although malignant transformation process is a 
recreation of tumourigenesis in vitro, the genomic alterations were not as striking as 
I expected which was very intriguing. The generation of focus definitely implied the 
presence of DNA damage, yet the changes occurred at this stage were not quite 
evolved. I then studied transcriptome changes that arose due to x-irradiation. Using 
principal component analysis and admixture analysis, I illustrated that the 
transcriptome profiles were distinctively differed according to x-irradiation or focus 
generation status. To investigate what drives focus generation, I analysed 
differentially expressed genes between un-irradiated cells and irradiated but non-
focus cells. Non-focus cells seemed to be at the initial stage of malignant 
transformation as its characteristics were closer to focus rather than un-irradiated 
cells. Particularly, non-focus cells exhibited highly elevated Cdkn1a, a DNA damage 
response gene, possibly to respond to DNA damage by x-irradiation. Also, down-
regulation of TGF- genes were observed in non-focus cells which may be one of 
the factors that induce focus generation. Moreover, DNA repair related genes 
including Atm, Atr, Brca1, Brca2, and Chek1 were highly elevated in focus cells. 
This study described that alterations due to x-irradiation in transcriptome were quite 
dramatic whereas changes in genome was rather gentle. Furthermore, as stem cells 
are frequently involved in malignant transformation, whether Focus possesses stem 
cell-like characteristics was examined. As a result, Focus displayed “stemness” and 
up-regulated Myc contributed to oncogenic reprogramming hence generated Focus 
cells with tumourigenic characteristics. In conclusion, I speculated that there are 
three factors involved in the second step of two-step malignant transformation. The 
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primary factor would be down-regulated Tgf gene expression. The change occurred 
in Non-focus, which is considered as at the very early stage of tumourigenesis. 
Decreased Tgf gene expression led the cells to transform further, hence induced 
DNA repair process especially error-prone DNA repair which would act as the 
secondary factor. Lastly, with up-regulated Myc oncogene, the cells were 
reprogrammed into cancer stem cell, hence generated foci with malignancy. Also, 
Focus cells exhibited stem cell-like characteristics. Taken together, in this study, I 
uncovered three factors that contributed to the second step of two-step malignant 
transformation and I believe that these findings will extend the understanding of 
tumourigenesis. 
---------------------------------------------------------------------------------------------------- 
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History of studying tumourigenesis  
Cancer occurs in various forms with numerous causes. Sometimes one significant 
driver gene mutation initiates tumourigenesis, but most cases, accumulated multiple 
mutations generate tumours [1]. For many decades, there had been many attempts to 
solve the underlying mechanism of tumourigenesis. However, cancer still is the 
disease which threats human life the most.  
 In the modern society, the life expectancy is dramatically increasing and 
prolonged lifetime drew more attention to cure of lethal diseases such as cancer in 
order to find a way to enhance the quality of health. There are various causes of lethal 
illnesses. Aging is the most common factor for initiating fetal diseases as one always 
go through physiological changes as part of natural life. It is a gradual and permanent 
process although not a pathological event. Aging does cause many disease including 
cancer, however, the most frequent cause of cancer is spontaneous mutations in genes 
that play a crucial role in tumourigenesis [2].  
 Cancer arises by somatic mutations in cancer driver genes such as 
oncogenes and tumour suppressor genes. For many years, the field of cancer research 
tried to find the causation of cancer. The very first insights on human cancer initiation 
was arisen in the 18th century [3]. From that time point, many intriguing thoughts 
and theories on tumourigenesis initiation were followed and in the early 20th century, 
Yamagiwa and Ichikawa reported their study on multistage and multifactor nature of 
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the tumourigenesis process using experimental technique [4]. Also, the first cancer 
virus was discovered in chickens by Ellerman and Bang [5] and Rous [6]. Then, a 
few decades later, Rous expanded his earlier studies on cancer virus and identified 
src oncogene, which is the first oncogene ever to be discovered in the history of 
cancer biology [6, 7].  
  Many hypotheses regarding finding the causes and consequences of 
tumourigenesis had been suggested. In the beginning, majority of cancer studies 
were focused on cytology and genetics using cellular and mouse model experiments. 
They were followed by researches that highlighted the importance of epigenetically 
controlled gene expression and genomic alterations in cancer to see the bigger 
picture and broaden the understanding of tumourigenesis. John Little and Ann 
Kennedy also proposed a hypothesis that there were two steps that contributed to 
tumour initiation and development. They believed that in the first step, an element 
from external environment, x-irradiation, induced changed characteristics of cells, 
then the second element altered the features of cells completely including their 
morphology. They called this hypothesis as “two-step hypothesis” and they provided 
some evidence by conducting cellular experiments [8].  
Two-step hypothesis of malignant cell transformation 
It is known that the accumulation of multiple genetic alterations is required for 
malignant transformation of a cell during tumour initiation or progression. In 1976, 
Little conducted an experiment to study x-irradiation induced oncogenic 
transformation in C3H10T1/2 cell line [9]. The foci were generated upon x-
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irradiation exposure and their oncogenic effect was confirmed using mouse model. 
Firstly, Little categorised formed foci according to their morphological features. 
Type 1 cells only showed unusual growth pattern but no obvious defected 
morphology. Type 2 and Type 3 were counted as transformed cells as Type 2 cells 
exhibited stellate features and most of Type 3 cells were piled up and formed multi-
layers of cells. The oncogenic effect of Type 2 and Type 3 focus was confirmed when 
tumour incidence was observed upon their injection. Tumours were formed when 
type 2 or type 3 focus cells were injected, not type 1. Then, a few years later, Little 
further investigated x-irradiation induced malignant transformation in C3H10T1/2 
cells [8, 10]. C3H10T1/2 cells were exposed to various intensities of x-irradiation, 
then cultured at optimum condition until confluence was reached. C3H10T1/2 cells 
were used as they are highly sensitive to post-confluence inhibition of cells division, 
therefore suitable cell line for transformation study. Average number of one focus 
per dish was generated after going through 12-13 rounds of cell division. When non-
focus cells from x-irradiated dish were re-seeded, they also formed focus after 
similar numbers of cell division at confluence. When normal cells reach at 
confluency, they become density inhibited. Transformed cells, however, display no 
sign of density inhibition which is one of the characteristics of transformed cells. It 
was very intriguing result that the focus was formed after going through certain 
numbers of cell division, not right after x-irradiation exposure. Based on this result, 
Little proposed that there were at least two steps involved in malignant 
transformation process. The hypothesis suggested by Little and Kennedy described 
that the initial damage was occurred due to x-irradiation, and then unknown element, 
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acted as a second hit, induced malignant transformation process. Therefore, Little’s 
experiments may be considered as an illustration of indirect tumour induction after 
x-irradiation. There were several subsequent studies regarding two-step malignant 
transformation including Little’s another investigation and Park et al.’s research [11]. 
In both studies, they tried to elucidate the factors that contributed to the second step 
of two-step malignant transformation. However, no clear answer was discovered at 
that time.                                                                           
Error-free and error-prone DNA repair system 
There are several reported studies suggesting defects in DNA repair system may 
increase the incidence of tumourigenesis [12]. In Escherichia coli (E. coli), when 
error-free repair system is saturated, as a last resort, error-prone repair system is 
activated and it is called the SOS system of bacteria [13-15]. The SOS system is 
usually responsible for ultraviolet (UV) induced mutations [14, 16], and the yield of 
DNA repair is quite low. This error-prone repair system may function in mutagenesis 
hence carcinogenesis. Here, I can speculate that Little’s experiment reflected that of 
DNA damaged E. coli. The x-irradiation firstly damaged DNA then altered some 
cellular processes which induced error-prone repair system, hence slowly generated 
transformants. In 1980s, the whole process was obscure and vague but I was able to 
anticipate that error-prone repair system in mammalian cell that is similar to the SOS 
system existed and contributed to malignant transformation [17]. I believe that x-
irradiation indirectly turned on the error-prone repair system and promoted the 
generation of transformants. Unfortunately, without having full knowledge on gene 
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expression profile or genomic alterations, some parts remained unanswered.  
Several decades later, in this study, I performed further analysis to give 
answers to unsolved questions using next-generation sequencing (NGS) technology. 
In the past, with experimental based studies, it was quite challenging to elucidate the 
causes and consequences of tumourigenesis. However, in recent years, various 
techniques that can identify genomic and transcriptomic characteristics of cancer. 
With NGS method, vast amount of information could be found and utilised to study 
tumourigenesis. The NGS techniques have definitely expanded the field of cancer 
biology and even help to discover therapeutic targets of cancer.  
Application of next-generation sequencing 
Next-generation sequencing, also known as massively parallel or deep sequencing, 
is now considered as a gold standard method in the field of cancer genomics which 
gives faster and more accurate results when compared to traditional Sanger 
sequencing [18-20]. This method revolutionised the whole field of genomic research. 
The traditional Sanger sequencing is considered as the first-generation sequencing 
technique, and NGS, the second-generation sequencing, delivers vast amount of high 
throughput data with reduced expense. Thus, this extraordinary technology has 
opened a new chapter of cancer biology and cancer genomics.  
 The applications of NGS are diverse and new systems are being developed 
continually. These applications can be categorised based on the purpose of the study.  
 (1) To build a brand-new reference genome from known or unknown 
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organism, de novo sequencing technique may be applied. Usually, de novo 
sequencing denotes to sequencing a unique genome where there is no reference 
sequence accessible for alignment. However, to improve the quality of result and to 
discover population specific genetic variation, the reference genome can be rebuilt. 
In 2016, Seo et al. generated AK1 genome reference which is based on Korean 
human genome [21]. Although human genome reference already exists, the need for 
population specific reference always remained. The establishment of AK1 human 
genome reference fulfilled these needs by providing more accurate result of genetic 
variation for Korean patients.  
 (2) To study human genetic variation, whole-genome sequencing (WGS) or 
whole-exome sequencing (WES) techniques can be applied using existing reference 
genome [22, 23]. Obtained sequencing results are compared with reference genome, 
then researchers can find the genetic variations including single-nucleotide 
polymorphisms (SNPs), structural variations, and somatic copy number alterations.  
 (3) To elucidate the gene expression pattern, RNA sequencing (RNA-seq) 
can be practiced. RNA-seq is a ground-breaking tool for transcriptome profiling [24]. 
It allows researchers to quantify gene expression level and characterise alternative 
splicing. Also, identifying novel transcript can be done using this particular method. 
Above all, the most appealing feature of RNA-seq is that the expression level of each 
gene can be compared and studied between groups of samples under various 
conditions [25-27].   
 (4) For epigenetic studies, DNA methylation may be analysed, and 
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sequencing methods such as bisulfite sequencing can be used. To determine 
methylation of CpG island, this technique is needed. Bisulfite treatment converts 
unmethylated cytosine to uracil so that only the methylated cytosine residues are 
identified. As altered methylation pattern is often observed in various types of human 
cancers, this tool offers valuable results that can characterise the DNA methylation 
profile of cancer cells [28, 29].    
 As mentioned above, NGS techniques hold many advantages including 
providing large amount of high throughput data as well as cost reduction. As the 
technique offers great extent of data, diverse genomic variations and gene expression 
patterns can be studied. The technique can be applied in the field of clinical research 
such as diagnosis of rare disease using molecular markers, non-invasive parental 
diagnosis, and of course, cancer biology [30, 31].  
Study scheme  
Lately, with greatly advanced NGS technology, many unsolved questions now have 
answers to them. Here, I reproduced Little’s experiment, then performed in-depth 
analysis using WGS and RNA-seq method to elucidate the underlying causes of 
malignant transformation. The samples were grouped into three categories, un-
irradiated cells, irradiated but non-focus cells, and irradiated focus cells. Then those 
samples were subjected to genomic and transcriptomic analyses.  
In the present study, I described the effect of x-irradiation in initiation and 
progression of malignant transformation, in other words, tumourigenesis. It is 
reported that radiation can induce genomic instability in mammalian cells [32]. The 
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consequences of radiation-induced genomic instability include chromosomal 
rearrangements and gene expression changes [33]. Although it is reported that 
radiation does not directly initiate genomic instability, but still induces defective 
cellular response which leads to DNA damage or gene expression alteration, hence 
disturbs cellular homeostasis [33-35]. Here, I examined the genomic and 
transcriptomic landscapes of two-step malignant transformation in x-irradiated 
C3H10T1/2 cells to discover the factors that contributed to the second step of 
malignant transformation. I believe that this study will improve our understanding 




MATERIALS AND METHODS 
Cell culture 
C3H10T1/2 cell line was purchased from ATCC (Cat. No. CCL-226; VA, USA). The 
cells were cultivated in Eagle's Basal medium with 2mM L-glutamine, 1mM sodium 
pyruvate, and 1500mg/L sodium bicarbonate (Cat. No. 30-2003; ATCC, VA, USA) 
containing 10% fetal bovine serum (Cat. No. 30-2020; ATCC, VA, USA) and 1% 
penicillin (Cat. No. SV30010; HyClone, UT, USA) and incubated at 37℃ in 5% 
CO2. The cells were counted using hemocytometer and approximately 4.0 x 105 cells 
were seeded in 100mm culture dish (Falcon 100mm TC-treated cell culture dish, Cat. 
No. 353003; Corning, NY, USA). Upon focus formation, the cells that were 
subjected to RNA-seq and WGS were obtained using cylinder isolation technique 
(Scienceware cloning cylinders, Cat. No. C3858-50EA; Sigma, MO, USA) [9, 36].  
X-irradiation 
C3H10T1/2 cells were exposed to 400rads, 600rads, and 800rads of x-ray at 
300cGy/min dose rate. The x-irradiation was directly exposed to culture dish. Varian 
6EX linear accelerator (Clinac iX system linear accelerator; Varian, CA, USA) was 
used for x-irradiation.  
Cell imaging 
The cell images were taken before x-irradiation and after focus formation (Leica 
DFC490; Leica Microsystems, Wetzlar, Germany). The magnification for the cell 
image was x100.   
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Giemsa staining  
To confirm focus formation giemsa staining was performed. Briefly, the cells were 
washed with 1X PBS (Cat. No. LB004-01; Welgen, Korea), then fixed with 4% 
paraformaldehyde solution (Cat. No. P2031; Biosesang, Korea) at room temperature 
for 30min. Next, diluted giemsa stain solution (Cat. No. 32884-250ML; Sigma, MO, 
USA) was placed on the culture dish at room temperature. After 2hrs, the dish was 
washed with 1X PBS then air dried. Blue stain represented focus. The images were 
taken by Cannon EF 50mm F1.2L USM camera.  
RNA sequencing 
RNA was extracted from each group of cells, non-irradiated, irradiated non-focus 
cells, and irradiated focus cells, using Easy Spin RNA extraction kit (Intron, Daejeon, 
Korea). Extracted RNA underwent quality and concentration measurement using 
NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA). Then, the RNA-
seq was performed on a HiSeq 2000 platform (Illumina, San Diego, CA, USA). The 
sequenced paired-end reads were aligned to mm10 mouse reference genome using 
STAR 1-pass method [37, 38], then PCR duplicates were removed by using Picard 
MarkDuplicate (http://picard.sourceforge.net). The filtered reads underwent further 
processing for variant calling using the best-practice of GATK 
(https://software.broadinstitute.org/gatk/best-practices) [39, 40]. The summary of 




Whole-genome sequencing  
Extraction of DNA was performed using QIAamp DNA mini kit (Cat. No. 51304; 
Qiagen, Hilden, Germany). WGS using Hiseq 2000 sequencing platform (Illumina, 
San Diego, CA, USA) was performed according to manufacturer’s instruction. 
Paired-end reads were aligned to GRCh37.p13 reference using BWA [41]. The 
sequencing summaries of WGS are provided in Table 2. Duplicated reads were 
removed by Picard tools (https://broadinstitute.github.io/picard/). MuTect was used 
for somatic SNV calling [42]. Somatic SNVs with PASS flag were annotated by 
ANNOVAR [43]. To identify somatic translocations, we used CNVKit [44].  
Differentially expressed gene analysis 
Based on Ensemble gene set, the number of reads aligned to each gene were counted 
using HTSeq-count then normalized via regularized log transformation using 
DESeq2 [26, 45]. Here, differentially expressed genes (DEGs) were determined by 
DESeq2 with q-value < 0.05, |Log2 (fold-change)| ≥ 0.6, and baseMean ≥ 100.   
Admixture analysis 
To examine the potential structure of gene expression data by clustering genes 
CountClust (version 1.3.1) was used [46, 47]. The variance stabilizing transformed 
expression values from DESeq2 were used for this analysis following the 
developer’s instructions [26, 48]. The number of genes that consisted each cluster 




Weighted correlation network analysis 
WGCNA was used to identify the relationship between gene expression changes in 
samples with focus generation status [49]. The detailed methodology is described in 
our previous study [50]. In brief, pairwise correlations between the expression of 
each gene were used to generate modules which represent the co-expression 
networks. To identify the associations of the constructed modules and the clinical 
traits, the correlation between modules and clinical features were defined using the 
Pearson correlation coefficient. The variance stabilizing transformed expression 
values from DESeq2 were used for the analysis [26, 48]. 
Pathway enrichment analysis 
The pathway enrichment analysis, which estimates biologically significant pathways 
using overlaps of genes of interest with particular gene sets or pathways, was 
performed using the Molecular Signature Database (MSigDB) version 6.0. Genes 
that were involved in differentiating focus cells from non-focus cells and control 
cells from irradiated non-focus cells were subjected to the analysis in addition to 
genes that contributed in distinguishing characteristics of focus cells and non-focus 
cells by constructing statistically significant modules in WGCNA. Two databases 
from MSigDB were utilised for the analysis: the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway and Hallmark (HM) gene set [51, 52]. KEGG is an 
important source for comprehending biological systems, organisms, and even the 
ecosystem. The database was constructed from combined data of genome sequencing 
and high-throughput experiment results. HM gene sets encapsulated and 
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characterised precise biological status or procedures and the gene sets were created 
using computational methodology.  
Somatic copy number variations 
To observe somatic copy number alterations CNVkit was used. CNVkit calculated 
and visualised copy number of samples from DNA sequencing data using Python 
library and command-line [44, 53, 54].  
Structural variations 
Delly2 computed structural variants using integrated prediction method. Variations 
such as deletions, duplications, inversions and translocations at single-nucleotide 
level from sequencing data can be discovered [55].   
Mutational signature analysis 
Somatic mutational signatures were identified using SomaticSignature R package 
[56]. This R package delivered accurate and efficient form of the somatic motifs 
according to a record of somatically mutated genomic sites and the prediction of 
somatic signatures with mathematical algorithms. The estimated mutational 
signatures from study subjects were compared with previously defined signatures on 






X-irradiation altered cell morphology and induced transformation of 
C3H10T1/2 cells 
The x-irradiation induced malignant cell transformation experiment was reproduced 
using similar protocol from Kennedy et al. [8] (Figure 1). C3H10T1/2 cells were 
exposed to different intensities of x-irradiation, 400rads, 600rads, and 800rads, then 
cultured until confluency. After numerous numbers of cell divisions, foci were 
formed. The number of focus formed was not highly affected by the intensity of x-
irradiation (Figure 2A), however, the time taken until focus formation was reduced 
for re-seeded (2nd seeding) cells (Figure 2B). The formation of focus was observed 
under microscope (Figure 3A) then confirmed with Giemsa staining (Figure 3B). 
The morphology of transformed cells was quite differed from that of normal. The 
cells were no longer growing in monolayer but piled up and displayed dense growth 
with stellate characteristics [9]. In previous study, Little categorised foci into three 
groups according to the morphological characteristics. Type 1 was not considered as 
focus but Type 2 and 3 were scored as focus as they exhibited significantly disrupted 
morphology including stellate shape [9, 11]. In this study, majority of observed foci 
were found as type 3 focus (Figure 3C).  
 In 1980, Little and Kenney proposed two-step hypothesis and suggested 
that x-irradiation induced malignant transformation is two-step process. When this 
experiment was firstly performed almost 40 years ago, not sufficient technology was 
available to further elucidate the genomic and transcriptomic characteristics. Several 
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decades later, in this study, using next-generation sequencing method, I identified 
the genomic and transcriptomic characteristics of x-irradiated non-focus cells and 
transformed focus cells hence uncovered the second factor of two-step hypothesis 
which Little originally proposed.  
Somatic copy number variation induced by x-irradiation 
To observe genomic changes due to x-irradiation, WGS was performed (Table 1 and 
Table 2). For genomic analysis, 14 samples were subjected including two un-
irradiated cells (hereafter referred as Control), four irradiated but non-focus cells 
(hereafter referred as Non-focus), and eight irradiated focus cells (hereafter referred 
as Focus). In human cancers, there usually are a few driver mutations that initiated 
cancer development and various types of chromosome rearrangements or copy 
number changes are observed [58, 59]. As this experiment mimicked malignant 
transformation in vitro, I expected a small number of driver mutations as well as 
chromosome aberrations to be found. However, genomic alterations induced by x-
irradiation were very mild. In case of somatic copy number variation (SCNV), the 
alteration patterns were not easily distinguishable according to the focus status 
(Figure 4). Non-focus group exhibited slightly less deletion or duplication of 
chromosome segments when compared to Focus but the SCNV patterns were very 
similar to each other. In mammalian cells, SCNV functions importantly in generating 
essential variations in the population as well as disease phenotype [60]. Here, x-
irradiation did not initiate dramatic changes in genome in terms of copy number 
variation. Gentle genomic alterations might suggest that focus generation may be 
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affected by other factors such as alterations in transcriptome [61, 62].  
Tumour mutation burden of x-irradiated cells 
In recent years, the prevalence of somatic mutation across human cancers was 
measured to elucidate the characteristics of diverse types of cancers [57]. Even 
though Non-focus and Focus cells are not fully developed tumour cells, as they 
presented tumourigenic features, tumour mutation burden (TMB) was measured. In 
human cancer, depends on cancer type, TMB varied. Some cancers displayed high 
prevalence of somatic mutations such as melanoma and lung squamous cancer and 
some other cancer exhibited comparatively low prevalence for example thyroid 
cancer and pilocytic astrocytoma. The number of somatic mutation found from Non-
focus and Focus samples were extremely low when compared to human cancer 
samples and when Non-focus and Focus were compared, the TMB were quite similar 
to each other (Figure 5). Moreover, the majority of SNPs from Non-focus and Focus 
were overlapped. Not only low number of SNPs were observed across all samples, 
but also the mutated genes were quite similar between samples (Table 3). This result 
once again reinforced that x-irradiation did not induce strong genomic alteration.   
Mutational signatures of x-irradiated cells 
Although Non-focus and Focus did not exhibit high tumour mutation burden, I 
speculated that there might be some signatures among low number somatic 
mutations. In human cancer, various types of mutational signatures were found by 
large-scale analyses [57, 63-66] and catalogue of somatic mutations in cancer, 
COSMIC, provided a spectrum of information on each mutational signature and 
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aetiology as well as additional mutational features [57]. Among 30 signatures from 
COSMIC, only one mutational signature, signature 5, was found in Non-focus and 
Focus samples (Figure 6). Signature 5 has been found in almost all types of cancer 
which may suggest that Non-focus and Focus samples possess certain properties of 
cancer.  
Confirmation of samples using the number of SNPs 
Since the focus represented malignantly transformed cells, substantial amount of 
genomic alteration was expected but the result turned out to be otherwise. 
Consequently, these gentle genomic changes led myself to focus on profound 
transcriptomic analysis. To make sure the samples subjected for WGS and RNA-seq 
were arose from the same specimen, the number of SNPs from each sequencing 
scheme were compared.  
 Firstly, the number and types of SNP detected from WGS and RNA-seq 
were investigated. Then, the overlapped SNPs and exclusive to WGS or RNA-seq 
were counted (Figure 7; Table 4). As average of 93% of SNPs were overlapped in 
each sample, I was able to conclude that the same samples were subjected for WGS 
and RNA-seq. 
Characteristics of x-irradiation induced transformed cells  
For transcriptome analysis, 17 samples were subjected including three Control, six 
Non-focus, and eight Focus (Table 1) and the summary of RNA-seq is shown in 
Table 5. When all samples were subjected to the principal component analysis (PCA), 
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a clear distinction between groups was exhibited (Figure 8A). Also, abundant 
number of DEGs were discovered including 2,083 up-regulated and 3,867 down-
regulated genes in Foci (Figure 8B). Genes such as Myc, Myct1, Mmp16, Mmp25, 
Mmp28, Fgd3 and Chek1 showed elevated expression levels in Focus. It is reported 
that increased expression of Myc contributes to tumourigenesis [67, 68] and over-
expressed and/ or activated Myc gene is frequently observed in various types of 
human cancers [69-75]. Also, it is known that some matrix metalloproteinases 
(MMPs) are involved in cancer progression [76-79]. In addition, there were a few 
down-regulated genes including Tgfb2, Tgfb3, Tgfbr2, Olfm2 and Adamts8. In case 
of TGF- genes, they differ in roles depend on tumour stage. TGF- genes display 
down-regulation in early stage cancer and show up-regulation in advanced stage [80]. 
Focus cells might not represent fully developed tumour cells. However, they did 
undergo malignant transformation process, hence they were considered as very early 
stage cancer cells which may explain down-regulated TGF- genes.  
Afterwards, to estimate the cellular status using gene expression pattern, I 
used CountClust which illustrated the potential structure of RNA-seq expression data 
by clustering genes [46]. Two distinctive clusters were identified and genes that 
compose each cluster were subjected to the further analysis. Genes from cluster 1 
were up-regulated in Control and displayed down-regulation in Non-focus then 
further down-regulation was observed in Focus. Conversely, cluster 2 showed the 
opposite trend. Genes from cluster 2 showed a trend of increment when cells went 
through phases from Control to Non-focus to Focus (Figure 9A). When genes from 
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each cluster were subjected to the pathway enrichment analysis, cluster 2 showed 
particular enrichment in ‘DNA replication’, ‘cell cycle’, and ‘pyrimidine metabolism’ 
(Figure 9B; Table 6). Here, the pathway enrichment results distinctly displayed that 
genes from cluster 2 illustrated focus-like characteristics and there was clear 
distinction in gene expression level between groups according to the presence of 
focus.  
Features of Non-focus cells  
To uncover which element behaves as a second factor in two-step malignant 
transformation, I focused on elucidating the features of Non-focus samples. 
Although Non-focus cells did not go through entire malignant transformation 
process, due to x-irradiation exposure, I was very positive that cells were damaged. 
The PCA using all samples revealed that Non-focus samples formed a separate 
cluster hence were distinguishable from un-irradiated cells (Figure 10A). Based on 
the differed gene expression pattern, I speculated that the hidden agenda of Little’s 
hypothesis probably lies underneath transcriptome profile of Non-focus.  
In the present study, after identifying diverged transcriptome profiles of 
Control and Non-focus, I examined DEGs. The volcano plot displayed 1,510 up- and 
618 down-regulated DEGs (Figure 10B). Genes including Cytl1, Peg3, Cdkn1a, 
Mmp9, Trp53i11, Il6, and Myc were found to be up-regulated in Non-focus. From 
up-regulated DEGs, Cytl1 and Il6 are related to immune system [81, 82] and Peg3 
has a function in cell proliferation and p53-mediated apoptosis [83]. Also, Mmp9 is 
involved in tumour development and metastasis [84] and Myc functions as proto-
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oncogene which explains its frequent up-regulation in human cancers [69, 85]. In 
particular, Cdkn1a which encodes p21 protein and is closely controlled by p53 
showed significant increment in Non-focus. As Cdkn1a is well-known DNA damage 
response gene, to sense the DNA damage caused by x-irradiation, I speculated that 
the expression level jumped in Non-focus [86-88]. In case of down-regulated DEGs, 
Tgfb2, Tgfb3, and Tgfbr2 were discovered. As mentioned earlier, TGF- genes are 
deeply involved in tumour suppression and progression depends on the tumour stage. 
With this approach, I was able to determine that cells from Non-focus samples were 
definitely in a process of undergoing transformation process and holding potential 
for transforming into malignant cells.  
Tgf gene expression in early stage of malignant transformation process 
To further verify the traits of Non-focus cells, I analysed 618 down-regulated genes 
in Non-focus. The pathway enrichment result of those genes described that processes 
such as ‘Melanoma’, ‘Melanogenesis’, and ‘TGF- signaling pathway’ were down-
regulated in Non-focus samples (Figure 11A; Table 7). Interestingly, TGF- 
signaling pathway was found as one of the top 10 significantly enriched pathways 
which emphasized the importance of down-regulation of Tgf genes in malignant 
transformation process as several Tgf genes were discovered as down-regulated 
DEGs between Control and Non-focus as well as Non-focus and Focus (Figure 8B 
and Figure 10B). Thus, I postulated that Tgf genes play a crucial role in progression 
of malignant transformation. When the expression profile of genes that are involved 
in TGF- signaling pathway was observed, numerous genes exhibited decreased 
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expression in Non-focus and Focus samples (Figure 11B). Next, Tgf genes that 
were identified as DEGs were further studied and showed gradual down-regulation 
from Control to Non-focus, then Non-focus to Focus samples (Figure 12). Continued 
decrement of Tgf genes may imply that when these genes are ‘switched-off’ when 
malignant transformation is initiated and progressed.  
Elevated immune response and spatiotemporal dynamics of Cdkn1a in Non-
focus 
To further elucidate detailed characteristics of Non-focus, up-regulated DEGs were 
subjected to gene set enrichment analysis (GSEA). KEGG pathways and HM 
pathways were used for this analysis and I found that those genes were mainly 
enriched with immune system or immune response related pathways (Figure 13A; 
Table 8). The immune related genes displayed increased in expression level in Non-
focus but went down in Focus, similar to that of Control or slightly further down 
(Figure 13B). It is known that the immune system functions in two different ways; it 
can participate in protection from tumourigenesis as immune surveillance or may 
contribute to inflammatory response which is tumour promoting environment [89, 
90]. As Non-focus is positioned at early stage of transformation process, cells may 
fight back for the external attack. Thus, I speculated that up-regulation of immune 
response was due to turned-on immune surveillance system to prevent the occurrence 
of malignant transformation process. Then, decreased immune related genes in 
Focus may be caused by overloaded immune surveillance system hence interpreted 
as failed immune surveillance.   
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Furthermore, there was one gene that exhibited very peculiar expression 
pattern, Cdkn1a, P53 pathway related gene, which is already mentioned as one of 
the up-regulated DEGs. While four other P53 pathway related genes showed gradual 
up-regulation from Control to Non-focus to Focus, Cdkn1a showed dramatic 
increment in Non-focus from initial seeding then reduced in expression in other 
samples although it was still higher than that of Control (Figure 14). Cdkn1a is 
known as DNA damage sensing gene and a few previous researches provided 
evidences that Cdkn1a is rapidly recruited to DNA damage sites when double-strand 
breaks (DSBs) are induced [88, 91, 92]. Moreover, it is a regulator of cell cycle upon 
DNA damage, but also a regulator of DNA repair [86, 93, 94]. In addition, Cdkn1a 
is also involved in P53 pathway and genes that are engaged in this pathway showed 
slight increment in Non-focus when compared to Control (Figure 15A). Interestingly, 
further up-regulation of P53 pathway related genes were displayed in Focus when 
compared to Non-focus (Figure 15B). P53 pathway is one of the major pathways that 
plays a role in tumourigenesis by regulating cell cycle and activating DNA repair 
process [95]. It is up-regulated upon external stress or DNA damages to prevent 
tumourigenesis. In the present study, upon x-irradiation, P53 pathway was activated. 
When the effect was accumulated in cells, which lead to focus generation, P53 
pathway was further raised. Here, I believe that slight increment of P53 pathway in 
Non-focus and dramatic increase in Focus may once again suggest that Non-focus 
cells were one step behind from developing into transformants and Focus represented 




Down-regulated immune system and histone genes in transformed cells  
Weighted correlation network analysis (WGCNA) was used to investigate the 
transcriptomic difference between each sample group according to the presence of 
focus. I identified 10 modules, five of which were statistically significant (Figure 
16A). Turquoise (r = -0.78 and p = 2E-04) and pink (r = -0.54 and p = 0.02) module 
showed a trend of decrement with presence of focus and brown (r = 0.74 and p = 7E-
04), blue (r = 0.51 and p = 0.04), and yellow (r = 0.5 and p = 0.04) exhibited 
otherwise. When the transcriptome profile of all genes from each significant module 
were illustrated clear up- and down-regulation of each module were observed (Figure 
16B). Interestingly, genes from pink module displayed intriguing transcriptomic 
profile. There was a sudden up-regulation in Non-focus, then showed steep down-
regulation in Focus whereas turquoise module showed gradual decrease from 
Control to Non-focus then to Focus samples. When down-regulated modules were 
subjected to the pathway enrichment analysis, turquoise module was enriched with 
‘pathways in cancer’, ‘regulation of actin cytoskeleton’, and ‘focal adhesion’. In case 
of pink module, pathways such as ‘systemic lupus erythematosus’, ‘viral myocarditis’ 
and ‘cytokine-cytokine receptor interaction’ were found to be enriched (Figure 17; 
Table 9). Intriguingly, there were five histone genes in pink module (5/183), Hist1h4i, 
Hist1h3d, Hist1h4h, Hist1h2bf, and Hist1h4k which were enriched with ‘systemic 
lupus erythematosus’. When DEG analysis was performed with all samples, 24 
histone genes were found as down-regulated genes in Focus including above five 
histone genes from pink module (Figure 18). It is known that declined immune 
system may contribute to establish tumour-promoting environment by diminishing 
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immune surveillance [89]. Also, down-regulation of histone genes upon DNA 
damage was also previously reported and this result reflected their conclusion [96]. 
Therefore, down-regulated histone gene expression may be considered as one of the 
characteristics of transformed cells. 
Defected DNA repair pathways and cell cycle regulation in Focus  
Various biological processes can get deregulated due to external stimuli including 
DNA repair process and cell cycle regulation. X-irradiation is a type of external 
stimuli which can introduce DNA damage in cells. Here, brown module exhibited 
up-regulated DNA repair process including ‘homologous recombination’, ‘mismatch 
repair’, and ‘base excision repair’ as well as ‘cell cycle’ and ‘DNA replication’ 
(Figure 19; Table 10). Pathways that were mainly enriched with blue module were 
mitochondrial function related pathways such as ‘oxidative phosphorylation’, 
‘Parkinson’s disease’ and ‘proteasome’ (Figure 19; Table 10). For yellow module, 
‘WNT signaling pathway’ and ‘Ubiquitin mediated proteolysis’ were found (Figure 
19; Table 10). 
Focus formation may indicate that cells are experiencing malignant 
transformation process, yet it does not mean that focus cells are fully developed 
tumour cells. Therefore, as the transformation process is still ongoing, the 
characteristics of Focus cells may not be consistent, hence, both tumour-promoting 
and -preventing characteristics can co-exist at this stage. In this study, elevated 
apoptotic genes and DNA repair processes were observed in Focus samples. As 
Focus are considered as transformants, damaged DNA repair system and 
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dysregulated cell cycle process were may be expected. In the present study, I focused 
on genes that are deeply involved in those processes. Atm and Atr are well-known 
DNA damage response genes and DNA damage response signaling pathway is 
orchestrated by above two genes [97]. They are found in yellow module and greatly 
involved in broad spectrum of biological processes in order to maintain genomic 
integrity including apoptotic process [98]. Upon x-irradiation, Atm sensed DNA 
damage, it directly activated Trp53, then activation of various pro-apoptotic genes 
was followed (Figure 20). When pro-apoptotic genes were further analysed, 
continued elevation of those genes from Non-focus to Focus were observed (Figure 
21A and 21B). In particular, Bak and Bax were found in blue and Apaf1 was found 
in yellow module, which were both up-regulated modules in Focus. Based on these 
findings, I speculated that apoptotic process is up-regulated as a compensatory 
mechanism to eliminate damages cells occurred during transformation process.  
Interestingly, Atm and Atr showed down-regulation in Non-focus then 
displayed up-regulation in Focus (Figure 22). As DNA repair and cell cycle 
regulation processes are affected by Atm and Atr, it is important to observe gene 
expression shift in genes that are related in those processes. Brca1, Brca2, and Chek1, 
that were all included in brown module, which also is an up-regulated module in 
Focus, were subjected to the analysis and they showed similar expression pattern as 
that of Atm and Atr. They all showed slight down-regulation in Non-focus then great 
up-regulation in Focus (Figure 22). Here, a schematic illustration of two types of 
DNA repair pathways described the inter-connected relationship of mentioned genes 
upon x-irradiation in Non-focus and Focus (Figure 23A and Figure 23B). When Non-
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focus and Focus were compared, DNA repair pathway related genes were more up-
regulated in focus. It is reported that when error-free repair pathway is overloaded, 
then error-prone repair is triggered as damaged DNA cannot be fixed with error-free 
way [13-15]. In this study, Focus samples exhibited saturated homologous 
recombination and as a result, increased non-homologous end-joining process was 
observed. As a response to damaged DNA and also as a compensatory mechanism, 
DNA repair process was up-regulated at the first place. Then, when the damage was 
too severe, error-free pathway became saturated, the cells had to choose turning on 
the error-prone repair pathway as a last resort. Thus, error was never completely 
fixed no matter how up-regulated the repair pathway was, hence focus was rigidly 
formed.   
In addition, there are Xrcc genes that show significant involvement in DNA 
repair processes [99]. Most of these genes are the components of different types of 
repair pathways such as homologous recombination (HR) and non-homologous end-
joining (NHEJ), hence comprehending the role of Xrcc genes may contribute to 
better understanding of human diseases including cancer. Among several Xrcc genes, 
Xrcc1, Xrcc2, Xrcc5, and Xrcc6 were increased in expression and enriched with up-
regulated modules in Focus (Figure 24). Xrcc1 and Xrcc6 were found in blue module 
and Xrcc2 and Xrcc5 were found in brown module. Xrcc1 exhibited an implication 
in general coordination of DNA base repair [100, 101] and Xrcc2 displayed RAD51-
like characteristics and involved in HR process [102-105]. Also, when Xrcc2 was 
defected in mouse model, increased apoptosis was observed [106]. Furthermore, 
Xrcc5 and Xrcc6 were engaged in NHEJ process [107, 108]. 
27 
 
Stemness of transformed cells  
Understanding how stem cells work will help to comprehend how diseases occur, 
how healthy cells are generated to substitute diseased cells or even testing new drugs. 
Although stem cells play an important role in tissue repair, there are also other studies 
that described the function of stem cells in malignant transformation and tumour 
initiation [109-112]. To observe whether focus cells hold stem cell-like 
characteristics, several chemical and genetic perturbations (CGP) gene sets from 
GSEA were used. Ramalho et al. discovered 195 up-regulated and 69 down-
regulated genes in embryonic, neural, and hematopoietic stem cells [113]. In my 
result, those genes were up-regulated and down-regulated respectively in Focus 
(Figure 25). Also, from CGP, Bhattacharya et al. represented 85 genes that displayed 
stemness signature with their up-regulation in six human embryonic stem cell (ESC) 
lines [114]. Moreover, Wong et al. found 328 genes that were up-regulated in mouse 
ESC that were overlapped with human ESC [115]. When those CGP gene sets were 
subjected to the analysis, Focus cells exhibited up-regulation (Figure 25). These 
findings suggested that transformed focus cells may have stem cell-like 




Table 1. The summary of sample information. 
Sample ID Dish of origin Seeding Focus status 
X-ray 1 A 1st No 
X-ray 2 A 1st Focus 
X-ray 3 A 1st Focus 
X-ray 4 B 1st No 
X-ray 5 B 1st Focus 
X-ray 6 B 1st Focus 
X-ray 7 A 2nd No 
X-ray 8 A 2nd Focus 
X-ray 9 A 2nd No 
X-ray 10 A 2nd Focus 
X-ray 11 B 2nd No 
X-ray 12 B 2nd Focus 
X-ray 13 B 2nd No 
X-ray 14 B 2nd Focus 
37_CON Control Control Control 
X-ray 16 Control Control Control 




Table 2. The summary of 14 WGS samples.   






X-ray 1 31.2 633096169 633096169 633096169 318698142 314398027 
X-ray 2 34.5 723945761 723945761 723945761 364275520 359670241 
X-ray 3 31.7 647992755 647992755 647992755 326316048 321676707 
X-ray 4 35.5 741950177 741950177 741950177 373358908 368591269 
X-ray 5 41.6 869578759 869578759 869578759 438092842 431485917 
X-ray 6 45 937592428 937592428 937592428 471792416 465800012 
X-ray 7 37.4 764499498 764499498 764499498 384509782 379989716 
X-ray 8 35 740063233 740063233 740063233 372810814 367252419 
X-ray 10 39.3 803911713 803911713 803911713 404080089 399831624 
X-ray 11 33.8 690418134 690418134 690418134 346452125 343966009 
X-ray 12 35.5 717960298 717960298 717960298 361182698 356777600 
X-ray 14 34.3 694497621 694497621 694497621 348959052 345538569 
X-ray 16 34.4 697239152 697239152 697239152 349620822 347618330 





Table 3. Somatic mutations found in all samples.  













































chr1 16103568 C A exonic Rpl7 
missense 
SNV 
R44L ./. ./. 0/1 0/1 ./. 0/1 0/1 ./. ./. ./. ./. ./. 
chr1 85212677 G T exonic Gm7609 
missense 
SNV 
V10L ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr1 85643260 A T exonic Sp140 
stopgain 
SNV 
K474X ./. ./. ./. ./. ./. ./. 0/1 ./. ./. 0/1 ./. ./. 
chr1 85643312 G T exonic Sp140 
missense 
SNV 
R491M ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. 
chr1 85643339 C T exonic Sp140 
missense 
SNV 
T500M 0/1 ./. ./. ./. ./. ./. 0/1 ./. ./. 0/1 ./. ./. 
chr1 85643343 C A exonic Sp140 
missense 
SNV 
F501L 0/1 ./. ./. ./. ./. ./. 0/1 0/1 ./. 0/1 ./. ./. 
chr2 89144852 G T exonic Olfr1223 
missense 
SNV 
P57H ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. 
chr2 111368761 T G exonic Olfr1283 
missense 
SNV 
L43R ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr2 164256266 C T exonic Svs3b 
missense 
SNV 
S45N ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. 
chr2 166081688 G A exonic Sulf2 
missense 
SNV 
A537V ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. 
chr2 176721008 G A exonic Gm14305 
missense 
SNV 
R231Q ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr2 176721428 G A exonic Gm14305 
missense 
SNV 
R371Q ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chr2 177832102 C T exonic Gm14325 
missense 
SNV 
G396S ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. 
chr3 53477969 C T exonic Proser1 
missense 
SNV 
A424V ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
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chr3 93215431 C A exonic Flg2 
missense 
SNV 
S1636Y ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 
chr3 93215770 G T exonic Flg2 
missense 
SNV 
G1749V ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 
chr3 93397577 G A exonic Rptn 
missense 
SNV 
R739Q ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. 
chr3 93446630 T G exonic Tchh 
missense 
SNV 
F1126V ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. 
chr3 93447158 T G exonic Tchh 
missense 
SNV 
F1302V ./. ./. 0/1 ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chr4 81365987 T G exonic Mpdz 
missense 
SNV 
E519D ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. 
chr4 126043633 G A exonic Csf3r 
missense 
SNV 
R662H ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr4 137428531 G A exonic Cela3b 
missense 
SNV 
H22Y ./. ./. ./. ./. ./. ./. ./. 0/1 ./. 0/1 ./. ./. 
chr4 145622307 T A exonic Gm13212 
missense 
SNV 
Y105N 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr4 146124202 A G exonic Gm13051 
missense 
SNV 
D68G ./. ./. ./. ./. ./. ./. 0/1 ./. ./. 0/1 ./. ./. 
chr4 146124571 A C exonic Gm13051 
missense 
SNV 
K191T ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. 
chr4 146125350 C G exonic Gm13051 
missense 
SNV 
L451V 0/1 ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. 
chr4 146125423 A T exonic Gm13051 
missense 
SNV 
E475V ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 
chr4 146125702 G T exonic Gm13051 
missense 
SNV 
R568I ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 0/1 ./. ./. 
chr4 146195532 G A exonic Zfp600 
missense 
SNV 
D257N ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chr4 146195808 C T exonic Zfp600 
missense 
SNV 
H349Y ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
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chr4 146196088 C A exonic Zfp600 
missense 
SNV 
T442K ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. 
chr4 147057808 A T exonic Rex2 
missense 
SNV 
Y251F ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr4 147058116 C T exonic Rex2 
missense 
SNV 
R354C ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chr4 147058728 C T exonic Rex2 
missense 
SNV 
P558S ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. 0/1 
chr4 147674949 G C exonic Zfp534 
missense 
SNV 
S421C ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 
chr4 147675066 C T exonic Zfp534 
missense 
SNV 
C382Y ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. 
chr4 147675508 T A exonic Zfp534 
missense 
SNV 
T235S ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr4 147675617 T G exonic Zfp534 
missense 
SNV 
K198N 0/1 ./. ./. ./. 0/1 ./. ./. 0/1 ./. ./. ./. ./. 
chr4 147675639 T G exonic Zfp534 
missense 
SNV 
K191T ./. ./. ./. ./. 0/1 ./. 0/1 ./. ./. ./. ./. ./. 
chr4 147755911 T G exonic Gm13157 
missense 
SNV 
E161A 0/1 ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chr4 147757804 C T exonic Gm13157 
missense 
SNV 
A19T ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. 
chr5 14934158 C T exonic Speer4e 
missense 
SNV 
E215K 0/1 ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. 
chr5 15621800 A G exonic Speer4d 
missense 
SNV 
H101R ./. ./. ./. 0/1 0/1 0/1 ./. 0/1 ./. ./. ./. 0/1 
chr5 26086441 C A exonic Gm10471 
missense 
SNV 
K122N ./. 0/1 0/1 0/1 ./. ./. 0/1 0/1 ./. ./. 0/1 0/1 
chr5 26086487 A T exonic Gm10471 
missense 
SNV 
F107Y ./. ./. ./. ./. ./. ./. 0/1 0/1 ./. ./. ./. ./. 
chr5 26105203 A G exonic 5031410I06Rik
missense 
SNV 
L30P ./. ./. ./. ./. ./. ./. 0/1 0/1 ./. 0/1 0/1 ./. 
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chr5 33664389 A C exonic Tacc3 
missense 
SNV 
E164D ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. 
chr5 93182981 A G exonic Ccni 
missense 
SNV 
M377T ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. 
chr5 93183011 G T exonic Ccni 
missense 
SNV 
P367H ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. 
chr5 94383818 A G exonic AA792892 
missense 
SNV 
N187S 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr5 109086448 G A exonic Vmn2r12 
missense 
SNV 
P633S 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr5 112839687 G T exonic Myo18b 
missense 
SNV 
P1037H ./. ./. ./. ./. ./. ./. 0/1 ./. ./. 0/1 ./. ./. 
chr5 113819688 G T exonic Selplg 
missense 
SNV 
Q186K ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. 
chr5 121208858 T C exonic Rpl6 
missense 
SNV 
V272A ./. 0/1 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr5 137520039 G T exonic Gigyf1 
missense 
SNV 
R165L ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. 
chr5 146556209 G A exonic Gm3402 
missense 
SNV 
A16T 0/1 ./. 0/1 ./. ./. 0/1 0/1 0/1 0/1 0/1 ./. ./. 
chr6 127949827 G T exonic Tspan11 
missense 
SNV 
R246L ./. 0/1 0/1 ./. 0/1 0/1 0/1 0/1 0/1 ./. 0/1 0/1 
chr6 128620279 C G exonic Klrb1a 
missense 
SNV 
V59L ./. ./. 0/1 ./. ./. ./. 0/1 ./. ./. ./. ./. 0/1 
chr6 132361427 C T exonic Gm8882 
missense 
SNV 
S276N ./. ./. ./. ./. ./. ./. 0/1 0/1 ./. 0/1 ./. ./. 
chr7 4919583 A C exonic Zfp628 
missense 
SNV 
Q268P ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. 
chr7 18426174 T C exonic Psg28 
missense 
SNV 
M366V ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chr7 18426192 C T exonic Psg28 
missense 
SNV 
V360I ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 
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chr7 18426377 C T exonic Psg28 
missense 
SNV 
G298D ./. 0/1 ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chr7 18478342 T C exonic Psg26 
missense 
SNV 
I363V ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. 
chr7 18652398 A T exonic Psg21 
missense 
SNV 
F221Y ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr7 38519652 T G exonic Gm5591 
missense 
SNV 
N599T ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. 
chr7 41044040 T C exonic Gm4884 
missense 
SNV 
S478P ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 
chr7 41286343 A G exonic Gm5592 
missense 
SNV 
T90A ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 
chr7 41288226 G C exonic Gm5592 
missense 
SNV 
E311Q ./. ./. 0/1 0/1 ./. 0/1 ./. ./. ./. 0/1 ./. ./. 
chr7 43226166 A G exonic EU599041 
missense 
SNV 
I216V ./. ./. 0/1 ./. ./. 0/1 0/1 ./. ./. ./. ./. ./. 
chr7 44251482 C A exonic 2410002F23Rik
stopgain 
SNV 
Y270X 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr7 44251493 C T exonic 2410002F23Rik
missense 
SNV 
A274V 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr7 109048037 A T exonic Ric3 
missense 
SNV 
I193N ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chr7 141859161 C A exonic Muc5b 
missense 
SNV 
P1948Q 0/1 ./. ./. ./. ./. ./. 0/1 ./. ./. 0/1 ./. ./. 
chr8 3459381 A C exonic Pex11g 
missense 
SNV 
V182G ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 
chr8 19732819 A G exonic 4930467E23Rik
missense 
SNV 
K124R ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chr8 20357039 G A exonic Gm15319 
missense 
SNV 
P224S ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. 
chr8 24962957 C T exonic Adam9 
missense 
SNV 
G778D ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. 
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chr8 24962958 C T exonic Adam9 
missense 
SNV 
G778S ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr8 27345850 T A exonic Tex24 
missense 
SNV 
L330M ./. ./. ./. ./. ./. ./. 0/1 ./. ./. 0/1 0/1 ./. 
chr8 40794988 C T exonic Adam20 
missense 
SNV 
P45L ./. ./. 0/1 ./. 0/1 ./. 0/1 ./. ./. 0/1 ./. ./. 
chr8 94521411 G A exonic Nlrc5 
missense 
SNV 
R1669H ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr9 89090621 T A exonic Trim43b 
missense 
SNV 
K160I ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. 
chr9 109286487 T C exonic Fbxw14 
missense 
SNV 
N72D 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr9 120018428 G A exonic Xirp1 
missense 
SNV 
S463L ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. 
chr10 100340907 C G exonic Gm4303 
missense 
SNV 
L18V 0/1 ./. ./. ./. ./. ./. 0/1 0/1 0/1 0/1 0/1 0/1 
chr10 100340932 G A exonic Gm4303 
missense 
SNV 
R26H 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr11 5032491 G A exonic Ap1b1 
missense 
SNV 
A624T ./. ./. 0/1 ./. 0/1 0/1 ./. 0/1 0/1 ./. ./. ./. 
chr11 58502494 G A exonic Olfr331 
missense 
SNV 
H27Y ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. 
chr11 58684277 C T exonic Olfr320 
missense 
SNV 
L135F ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. 
chr11 58758255 C T exonic Olfr316 
missense 
SNV 
H197Y ./. ./. 0/1 ./. 0/1 ./. ./. 0/1 ./. ./. ./. 0/1 
chr11 99785583 A G exonic Krtap4-9 
missense 
SNV 
Q110R ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. 
chr11 114893406 C T exonic Cd300a 
missense 
SNV 
A80V ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. 
chr11 114893412 G A exonic Cd300a 
missense 
SNV 
S82N ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. 
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chr11 116347440 A G exonic Rnf157 
missense 
SNV 
S533P ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr11 120347084 C G exonic Actg1 
missense 
SNV 
R210P ./. ./. 0/1 0/1 ./. ./. ./. ./. ./. ./. ./. ./. 
chr11 120347130 C T exonic Actg1 
missense 
SNV 
E195K ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr11 120347154 C T exonic Actg1 
missense 
SNV 
D187N ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr12 31074539 G A exonic Fam110c 
missense 
SNV 
A167T ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr12 86983623 A G exonic Zdhhc22 
missense 
SNV 
F184L ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chr12 111730089 C A exonic Apopt1 
missense 
SNV 
F152L ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. 
chr13 66122638 T A exonic Gm10324 
missense 
SNV 
H539Q ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. 
chr13 100162007 T C exonic Naip2 
missense 
SNV 
N507S ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. 
chr13 119949600 C A exonic B020031M17Rik
missense 
SNV 
G157C ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. 0/1 0/1 
chr14 42794859 G C exonic Gm10377 
missense 
SNV 
N113K ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. 
chr14 50515832 G T exonic Olfr742 
missense 
SNV 
M209I ./. ./. ./. 0/1 0/1 0/1 ./. ./. 0/1 ./. ./. 0/1 
chr14 51101527 C G exonic Ang 
missense 
SNV 
P42A ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chr14 54664562 G T exonic Acin1 
missense 
SNV 
S591Y ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. 
chr14 79453128 C A exonic Kbtbd6 
missense 
SNV 
P358H ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. 
chr15 78348350 G A exonic Csf2rb 
missense 
SNV 
S619N ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. 
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chr15 89424789 A C exonic Cpt1b 
missense 
SNV 
V70G ./. 0/1 ./. ./. 0/1 ./. 0/1 ./. ./. ./. 0/1 0/1 
chr15 91908701 G T exonic Muc19 
missense 
SNV 
S2076I 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr15 101947704 A C exonic Krt78 
missense 
SNV 
I557M ./. ./. ./. 0/1 ./. ./. ./. ./. 0/1 ./. ./. ./. 
chr16 32753750 G T exonic Muc4 
missense 
SNV 
V1209F ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. ./. 
chr17 15544509 T G exonic Prdm9 
missense 
SNV 
K670Q ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr17 20268350 C T exonic Vmn2r106 
missense 
SNV 
A596T ./. ./. ./. 0/1 ./. ./. ./. ./. ./. ./. ./. 0/1 
chr17 35323300 T G exonic H2-Q1 
missense 
SNV 
Y283D ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 
chr17 35554981 T A exonic Cdsn 
missense 
SNV 
S136T ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chr17 35619613 A G exonic Gm9573 
missense 
SNV 
L1227P ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 
chr17 56104806 A C exonic Plin4 
missense 
SNV 
S742A ./. ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. 
chr17 94876751 G A exonic Gm20939 
missense 
SNV 
G277S ./. ./. ./. ./. ./. ./. ./. ./. 0/1 ./. 0/1 ./. 
chr18 58056266 C A exonic Fbn2 
missense 
SNV 
R1596L ./. ./. 0/1 ./. 0/1 ./. 0/1 0/1 0/1 0/1 0/1 0/1 
chr19 60762120 A C exonic Eif3a 
missense 
SNV 
N1332K ./. 0/1 ./. ./. ./. ./. ./. ./. ./. ./. ./. ./. 
chrX 61184396 T C exonic Cdr1 
missense 
SNV 
Q388R ./. ./. ./. ./. ./. ./. ./. 0/1 ./. ./. ./. ./. 
chrX 73290421 G T exonic Xlr5c 
missense 
SNV 





Table 4. The number of SNPs found in WGS and RNA-seq.  
 RNA-seq only Common WGS only 
  RNA-seq WGS  







Table 5. The average RNA-seq summary of 17 samples. 





X-ray 1 57976963 52616491 90.75  
X-ray 2 65975292 59598866 90.34  
X-ray 3 77331102 70429872 91.08  
X-ray 4 88511140 80875924 91.37  
X-ray 5 76806638 69356984 90.30  
X-ray 6 77945767 70812724 90.85  
X-ray 7 75905005 68752643 90.58  
X-ray 8 59284103 52570998 88.68  
X-ray 9 75382149 67846665 90.00  
X-ray 10 85873980 77317134 90.04  
X-ray 11 76429057 68156009 89.18  
X-ray 12 91091763 80311451 88.17  
X-ray 13 70897805 63026807 88.90  
X-ray 14 76403307 67236244 88.00  
37_CON 74546548 68668509 92.11  
X-ray 16 80547809 73703094 91.50  
X-ray 17 66579474 60544875 90.94  
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Table 6. The top 10 significantly enriched KEGG pathways in Cluster 1 and 
Cluster 2. 
Cluster Pathway p-value q-value 
Cluster 1 
Pathways in cancer 1.30E-20 2.41E-18 
Focal adhesion 1.42E-18 1.32E-16 
Lysosome 3.41E-16 2.12E-14 
ECM receptor interaction 4.33E-15 2.01E-13 
WNT signaling pathway 3.86E-12 1.43E-10 
Melanoma 9.58E-12 2.97E-10 
Prostate cancer 2.86E-10 7.60E-09 
Regulation of actin cytoskeleton 9.11E-08 2.12E-06 
Calcium signaling pathway 1.32E-07 2.43E-06 
Pancreatic cancer 1.44E-07 2.43E-06 
Cluster 2 
Ribosome 1.42E-40 2.65E-38 
Cell cycle 7.31E-35 6.80E-33 
Focal adhesion 1.36E-22 8.42E-21 
Oocyte meiosis 7.68E-20 3.57E-18 
Regulation of actin cytoskeleton 1.51E-19 5.62E-18 
Dna replication 3.67E-17 1.14E-15 
Aminoacyl trna biosynthesis 3.84E-16 1.02E-14 
Pyrimidine metabolism 2.94E-13 6.84E-12 
Tight junction 8.37E-13 1.73E-11 





Table 7. The top 10 significantly enriched KEGG pathways using down-
regulated DEGs in Non-focus. 
Pathway p-value q-value 
Pathways in cancer 1.95E-12 3.63E-10 
Cytokine-cytokine receptor interaction 2.77E-10 2.58E-08 
ABC transporters 1.04E-07 6.47E-06 
Melanoma 2.96E-06 1.02E-04 
Drug metabolism cytochrome p450 3.25E-06 1.02E-04 
Melanogenesis 3.30E-06 1.02E-04 
WNT signaling pathway 7.80E-06 2.07E-04 
TGF-B signaling 1.07E-05 2.48E-04 
Focal adhesion 1.21E-05 2.50E-04 





Table 8. The top 5 significantly enriched KEGG pathways using up-regulated 
DEGs in Non-focus.   





NOD-like receptor signaling 
pathway 
1.30E-04 1.05E-02 
Pathways in cancer 1.70E-04 1.05E-02 
Focal adhesion 2.90E-04 1.35E-02 
Ether lipid metabolism 1.24E-03 4.61E-02 
Hallmark 
Interferon  response 3.14E-11 1.57E-09 
Inflammatory response 7.75E-07 1.94E-05 
IL6-JAK-STAT3 signaling 1.12E-05 1.86E-04 
Hypoxia 1.64E-05 2.05E-04 







Table 9. The top 10 significant KEGG pathways found in down-regulated 
modules in WGCNA.   
Module 
colour 
Pathway p-value q-value 
Turquoise 
Pathways in cancer 3.56E-24 6.61E-22 
Regulation of actin cytoskeleton 1.06E-22 9.90E-21 
Focal adhesion 3.02E-21 1.87E-19 
MAPK signaling pathway 2.25E-15 1.05E-13 
FC g R mediated phagocytosis 2.17E-13 8.07E-12 
Melanoma 1.27E-12 3.92E-11 
Neurotrophin signaling pathway 1.81E-12 4.82E-11 
Lysosome  3.12E-12 7.25E-11 





Systemic lupus erythematosus 3.57E-07 6.63E-05 
Calcium signaling pathway 2.74E-04 2.02E-02 
Melanogenesis 3.26E-04 2.02E-02 
Basal cell carcinoma 7.30E-04 2.86E-02 
Hedgehog signaling pathway 7.70E-04 2.86E-02 
Leishmania infection 1.60E-03 3.49E-02 









Table 10. The top 10 significant KEGG pathways found in up-regulated 
modules in WGCNA. 
Module 
colour 
Pathway p-value q-value 
Brown 
Cell cycle 4.91E-24 9.13E-22 
Homologous recombination 4.07E-14 3.79E-12 
DNA replication 2.09E-12 1.29E-10 
Oocyte meiosis 6.05E-10 2.81E-08 
Mismatch repair 2.36E-09 8.79E-08 
Purine metabolism 6.36E-07 1.85E-05 
Regulation of actin cytoskeleton 6.96E-07 1.85E-05 
Pyrimidine metabolism 1.15E-06 2.66E-05 
Base excision repair 2.04E-06 4.22E-05 




Huntington's disease 2.57E-64 4.79E-62 
Ribosome 1.23E-60 1.14E-58 
Oxidative phosphorylation 1.59E-49 9.87E-48 
Parkinson's disease 8.81E-49 4.10E-47 
Alzheimer's disease 2.57E-46 9.56E-45 
Splicesome 2.18E-35 6.75E-34 
Proteasome 1.19E-24 3.16E-23 
Purine metabolism 1.82E-20 4.23E-19 
Pyrimidine metabolism 2.82E-18 5.83E-17 
DNA replication 2.05E-17 3.81E-16 
Yellow 
WNT signaling pathway 1.99E-12 2.48E-10 
Ubiquitin mediated proteolysis 2.66E-12 2.48E-10 
Adherens junction 7.20E-10 4.47E-08 
Oocyte meiosis 3.53E-09 1.64E-07 
Focal adhesion 1.82E-08 6.38E-07 
Endocytosis 2.06E-08 6.38E-07 
Regulation of actin cytoskeleton 6.07E-08 1.60E-06 
Pathways in cancer 6.89E-08 1.60E-06 
Insulin signaling pathway 3.12E-07 6.44E-06 





Figure 1. Experimental scheme of malignant transformation in C3H10T1/2 cells. 
The number of cells initialed seeded was approximately 4.0 x 105 cells per 100mm 
dish. The cells were irradiated with 400/ 600/ 800rads of x-irradiation then cultured 
until confluency. Upon focus formation, non-focus cells from focus generated dish 






Figure 2. The number of focus generated and time taken for focus generation. 
(A) Number of focus generated and time taken for focus generation from 1st seeding. 






Figure 3. The cell images of Control cells and Focus cells. (A) Morphological 
difference was observed in focus cells. (B) Giemsa staining confirmed focus 








Figure 4. Somatic copy number variation in Non-focus and Focus samples. The 








Figure 5. Tumour mutation burden of Non-focus and Focus samples. The 







Figure 6. Signatures of mutational process in Non-focus and Focus samples. 






Figure 7. The number of SNPs from WGS and RNA-seq data. To confirm 
whether the subjected samples for WGS and RNA-seq were identical, the number of 




Figure 8. The transcriptomic profile of all samples. (A) Principal component analysis. The focus status divided the samples into two groups. 





Figure 9. Estimation of cellular status of all samples. (A) The transcriptome profile of all samples. Two distinctive clusters represented the 
difference between gene expression pattern of samples with focus and without focus. (B) Dot plot illustrated Top 10 the most significant KEGG 




Figure 10. The transcriptome profile of Control and Non-focus. (A) Principal component analysis. Control samples were evidently separated 




Figure 11. Down-regulated differentially expressed genes in Non-focus. (A) The top 10 the most significantly enriched KEGG pathways. (B) 




Figure 12. Relative expression levels of TGF- genes. TGF- genes showed down-







Figure 13. The characteristics of up-regulated genes in Non-focus samples when compared with Control. (A) Dot plot described the top 5 
KEGG and HM pathways that were enriched with up-regulated genes. (B) The heatmap illustrated immune response related pathways were 




Figure 14. Relative expression levels of increased genes in Non-focus. Expression 
level of P53 pathway related genes were observed. Four genes except for Cdkn1a 
displayed gradual increment in Non-focus, then Focus. Cdkn1a exhibited dramatic 
up-regulation in 1st Non-focus, then showed slight decrement in 2nd Non-focus and 





Figure 15. The schematic description of P53 signaling pathway. (A) Gene 
expression changes occurred in Non-focus samples when compared with Control and 





Figure 16. Weighted gene co-expression network analysis using all samples. (A) 
Module trait relationship of generated modules. The statistically significant modules 
were marked with asterisk. The correlation values and p-values (in the bracket) were 
shown. (B) The heatmap illustrated gene expression profile of five statistically 





Figure 17. Pathway enrichment result for two significantly down-regulated 





Figure 18. The expression pattern of histone genes in all samples. Focus samples 
showed decreased expression level of histone genes. The expression pattern of 





Figure 19. Pathway enrichment result for three significantly up-regulated 





Figure 20. The schematic description of apoptotic pathway. Pro-apoptotic genes 





Figure 21. Transcriptome profile of apoptosis related genes. (A) Relative gene 
expression level of apoptosis related genes. (B) Gene expression pattern of apoptosis 




Figure 22. Relative expression level of DNA repair pathway related genes. DNA 





Figure 23. The schematic description of DNA repair pathways in (A) Non-focus 




Figure 24. Relative expression level of Xrcc genes. Several Xrcc genes were 
elevated in Non-focus, then Focus and they were enriched with significantly up-






Figure 25. Expression profile of genes that describes stemness of transformed 
cells. Ramalho et al. represented 195 genes enriched in embryonic, neural, and 
hematopoietic stem cells and 69 genes depleted in embryonic, neural, and 
hematopoietic stem cells. Bhattacharya et al. discovered 85 genes showing stemness 
signature when up-regulated in six human embryonic stem cell (ESC) lines. Wong 
et al. found 328 core ESC-like genes that are up-regulated in mouse ESC which are 
shared with the human ESC-like genes. Focus cells exhibited stemness 






Defining tumourigenesis always has been an important but challenging task. In 
mammalian cells, compromised genomic integrity might serve as an “ignition switch” 
of tumourigenesis. There are various known factors that initiate tumourigenesis 
although many of them are not fully elucidated yet. Based on previous reports, 
genomic instability is one of the traits that defines cancer [116, 117] and genomic 
instability refers to events such as SNPs, and chromosomal rearrangements. In 
cancer genome, genomic instability may occur prior to or as a consequence of 
malignant transformation. Here, using next-generation sequencing approach, I 
uncovered the underlying contributing factors of malignant transformation of x-
irradiated cells.     
Malignant transformation is a process whereby cells obtain the properties 
of tumour. There are several theories regarding this event, and one of them was 
suggested by John Little in 1980. He proposed two-step hypothesis, yet, was not able 
to describe both factors that were involved in the two-step transformation process. 
However, a new era of genomics and transcriptomics was broadly opened, the 
unknown factors that contributed to malignant transformation now may be able to 
arise on the surface. Vast amount of data provided by NGS technology were 
interpreted in this study and, as a first step, genomic alterations were sought 
including copy number variations and driver mutations.  
Unexpectedly, genomic changes caused by x-irradiation were not severe. 
Although genomic instability is one of the traits that defines tumour, irradiation did 
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not directly initiate genomic instability [118]. However, irradiation generated 
defective cellular responses then induced DNA damage or gene expression alteration, 
which led to impaired cellular homeostasis. In this study, the cells damaged by x-
irradiation, but due to intracellular heterogeneity, the damaging effects varied 
between cells. This phenomenon also is a great challenge in precision cancer therapy 
as human cancers also exhibit intratumoural heterogeneity [119]. Here, the 
mutational signature result signified the heterogeneity of x-irradiated cells. The sole 
demonstration of COSMIC mutational signature 5 from both Non-focus and Focus 
samples illustrated each cell possesses tumour-like characteristics but the level of 
DNA damage differed, hence resulted in mixed population of cells, displaying 
heterogeneity. Perhaps with single-cell level analysis, this problem may be solved 
and I may be able to obtain more detailed information.  
Nevertheless, the formation of focus upon x-irradiation was very evident 
event and morphological changes were definite. In vitro result confirmed the 
existence of alterations in cells, although the major changes did not involve genomic 
alterations. Thus, I needed to look this matter with different angle and the answer 
was transcriptome analysis. Frequently, tumourigenesis resulted from collapsed 
homeostasis and it is also known as somatic evolution, it is crucial to fully understand 
the causes and the consequences of this process. In terms of cancer evolution, some 
studies reported that transcriptomic changes occur prior to genomic changes [61, 62]. 
Therefore, I focused on elucidating gene expression changes of Non-focus and Focus 
upon x-irradiation and showed several evidences which supported transcriptome 
changes may promoted malignant transformation upon x-irradiation.   
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Based on Little’s hypothesis, due to the first factor, x-irradiation, malignant 
transformation is initiated and Non-focus stage was reached prior to generate focus. 
Then, by the second factor, although unknown, focus was generated. Here, I can 
speculate that Non-focus stage is equivalent to very early stage tumour cell as it 
presented potential to develop into focus which is a form of tumour. Unleashing the 
traits of Non-focus would finally give an answer to two-step malignant 
transformation process, hence I focused on deciphering the transcriptome 
characteristics of Non-focus.  
One of the most interesting alterations in Non-focus when compared to 
Control was decreased expression of Tgf genes. Tgf genes have unusual aspect as 
they have dual roles depend on the tumour stage [120, 121]. It is also known as “Tgf 
paradox” since in early stage cancer, those genes play tumour suppressive role and 
induce growth arrest, but in later stage or advanced cancer, they act otherwise and 
promote tumour progression [120]. Down-regulation of Tgf genes was frequently 
observed in early stage cancer and their tumour suppressive role in early stage cancer 
is well-studied using mouse model system [80, 120, 122]. Various transgenes were 
used to generate mouse model of Tgf including dominant negative type 2 Tgf 
receptor (Tgfr2DN) and type 2 Tgf knockout receptor (Tgfr2null). In these mouse 
models, an increased occurrence of tumour emergence was observed which 
supported tumour suppressive role of Tgfgenes. The results from mouse models 
were in parallel with gene expression profile of Non-focus which supported our 
previous hypothesis. Non-focus samples seemed to be at the very early stage of 
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malignant transformation, or tumourigenesis, and down-regulated Tgf genes can be 
the driving factor for progression of malignant transformation.  
Moreover, another striking discovery was dramatic up-regulation of 
Cdkn1a in Non-focus, especially derived from 1st seeding plate. Cdkn1a is known as 
a DNA damage sensing gene and gets recruited to damaged sites and accumulated 
[91, 92]. For this reason, Cdkn1a sometimes used as DNA damage site detection 
marker [92]. Spatio-temporal dynamics of Cdkn1a is worth observing as the 
expression level of this gene in Non-focus cells from initially seeded plate was far 
more elevated than that of re-seeded ones. Several previously reported studies 
mentioned that the underlying mechanism for transformation of non-irradiated cells 
into malignant cells may be radiation-induced bystander effects [118]. One of the 
suggested evidence was p53-mediated bystander effect and upon -particle exposure 
on human skin fibroblasts, three- to four-fold increment was observed in p53 protein 
and its downstream gene Cdkn1a in bystander cells [123, 124]. Based on this result, 
I was able to deduct that elevated Cdkn1a gene expression is one of the signatures 
of Non-focus, in the reported study, bystander cells.  
As x-irradiation induced malignant transformation process, Focus samples 
reflected tumour cell characteristics. Immune system in response to irradiation 
damage, it can participate both in protection from tumourigenesis through immune 
surveillance or cause an inflammatory response hence contribute to tumour 
promoting environment. In Non-focus, immune response related genes were highly 
elevated to fight back from external attack. However, in Focus, down-regulation of 
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immune response was observed which can be interpreted as failed immune 
surveillance system. Here, once again, Focus samples exhibited tumour-like 
characteristics by showing collapsed immune surveillance system.  
Furthermore, DNA repair pathways were highly elevated in Focus. Usually, 
in human cancer, DNA repair pathways show frequent down-regulation [125, 126]. 
However, in this study, in Focus, repair pathways, both HR and NHEJ, were highly 
up-regulated, especially HR. One of previous studies described the relationship 
between oncogenic transformation in vitro by x-irradiation and its effect on repair 
process [127]. At that time, the clear association between two events were not fully 
elucidated. The study only described that upon x-irradiation, the survival of cells was 
declined which implied dysfunction of repair process. In this study, I tried to clarify 
the influence of dysregulated DNA repair process and progression of malignant 
transformation. Although elevated DNA repair process is not frequent event, it is 
reported that, in E. coli, when error-free repair system is saturated, error-prone repair 
is triggered and it is called as the SOS repair system [17]. In addition, in E. coli, it is 
known that the SOS system is mainly responsible for UV radiation induced damage 
[17]. Moreover, also in human lymphoblast cells, upon radiation-induced DSBs 
generation, they are usually repaired by NHEJ, not by HR [128]. Even though the 
damage is repaired by HR, the yield is very low [129, 130]. This study displayed 
parallel results from E. coli and Little’s experiment also showed the alternative error-
prone DNA repair system was activated when error-free repair pathway was 
overloaded. As it displayed indirect tumour induction via x-irradiation, at that time, 
the involved process might have been quite obscure and vague. However, one thing 
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that was clear was the SOS system was permanently activated by the x-irradiation. 
Therefore, low yield error-free repair pathway and error-prone repair system were 
not able to fix damaged DNA properly, hence the Focus cells with mutagenic DNA 
lesions remained unrepaired and underwent uncontrolled cell division then showed 
tumour-like characteristics. The similar trend was exhibited in apoptotic pathway. 
The damaged cells usually undergo cell cycle arrest, then experience apoptosis. Here, 
through compensatory mechanism, Focus tried to undergo apoptosis to eliminate 
damaged cells. Since both DNA repair mechanism and apoptotic pathway were not 
working properly, no matter how hard the Focus cells tried to fight back for the 
damage, the mission did not succeed and as a consequence, focus were rigidly 
formed.  
Based on findings from this study, transcriptome alterations contributed the 
most to two-step malignant transformation. However, gaining tumour-like 
malignancy characteristics during transformation process may need some additional 
explanations. Various studies reported that stem cell is involved in tumourigenesis. 
Stem cells are significant to tissue repair but they also have functions in malignant 
transformation and tumour initiation [109-112]. When ESC-like genes from CGP 
were analysed, Focus displayed similar expression pattern as ESCs which reinforced 
that Focus exhibits “stemness”. Moreover, it is reported that increased Myc oncogene 
is also involved in reprogramming cells. In fact, Myc alone is sufficient to activate 
ESC-like programme in normal or tumour cells [115]. It is also reported that tumour 
initiated by Myc is independent of genomic instability. In this study, Myc is up-
regulated in Focus and genomic alteration in Focus is very mild. Taken together, 
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“stemness” of Focus promoted the second step of two-step malignant transformation 
by reprogramming cells into cancer stem cell, hence allowed to gain malignancy in 
transformed cells. In conclusion, there are three factors involved in the second step 
of two-step malignant transformation process: down-regulated Tgf gene expression, 
activated error-prone DNA repair system, and “stemness” of Focus cells.    
From genomic and transcriptomic analyses, I was able to conclude that x-
irradiation induced focus generation represented tumourigenesis process in vitro, and 
the generated foci can be considered as very early stage cancer cells. I was able to 
identify the transcriptome profile of Non-focus and Focus and discovered the factors 
that contributed to the second step of Little’s two-step hypothesis. Having full 
knowledge on malignant transformation process is important as knowing this process 
may be the initial step for developing more efficient cancer treatments. The targets 
for conventional cancer therapies were usually found with genomic studies. However, 
with our approach, as sometimes transcriptome changes occur prior to genomic 
alterations, I believe that cancer can be detected at its earlier stage with 
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종양의 발생과 진화는 다양한 종류의 변이에 의해 활성화 된다. 1980년, 
Little과 Kennedy는 종양으로 되는 단계인 세포의 형질전환을 초래하는 
요인들을 밝히고자 C3H10T1/2 세포주에서 엑스레이를 이용하여 실험
을 진행하였다. Little은 two-step 이론을 제시하며 세포에서 x-선 조
사로 인해 유도되는 세포의 형질전환은 두 종류의 인자에 의해 일어난다
고 제안하였다. 두 종류의 인자 중 첫 번째 인자는 x-선 조사였으나 두 
번째 인자에 대해서는 자세하게 밝혀내지 못하였다. 40년의 세월이 지난 
오늘날, 본 연구에서는 차세대 염기서열 분석 기법을 이용하여 1980년
대에 미처 밝히지 못했던 형질전환을 초래하는 유전자군에 대해 밝히고
자 하였다. 먼저, 전장 유전체 분석 기법을 이용하여 x-선 조사로 유도
된 focus 형성과 유전형질의 변환과의 관계를 알아보고자 하였다. X-선
이 조사 되었으나 focus를 형성하지 않은 세포 (Non-focus) 와 focus
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가 형성된 세포 (Focus) 의 유전체 복제수 변이, 돌연변이 발생 원인에 
따른 고유한 특징 및 종양변이부담을 분석하였다. 그 결과 focus를 형성
하더라도 x-선이 조사된 focus를 형성하지 않은 세포에 비해 유전체의 
변화는 크게 없는 것이 관찰되었으며 x-선 조사가 유전체 변이에 큰 영
향은 주지 않는 것을 알 수 있었다. 그리하여 본 연구에서는 전사체 분
석 기법을 이용하여 x-선 조사로 유도된 focus 형성에 관여하는 유전
자 발현 패턴 변화를 연구해보고자 하였다. 주성분 분석과 admixture 
분석 결과는 focus 형성 여부에 따라 전사체 패턴이 달라짐을 보여주었
으며 focus 형성을 유도하는 인자를 차별발현 유전자 분석을 이용하여 
규명하고자 하였다. X-선이 조사되지 않은 컨트롤군과 Non-focus군의 
유전자 발현량과 패턴의 차이가 대조되었으며 그 결과, Non-focus군은 
엑스레이로 유도된 형질변형 과정의 가장 초기단계에 있다는 것을 설명
할 수 있었다. 또한, Non-focus군의 전사체 기질이 컨트롤군 보다는 
Focus군에 더 가깝다는 것도 밝혀졌다. 특히, Non-focus군에서는 DNA 
손상반응 유전자로 잘 알려진 Cdkn1a가 엑스레이로 인한 DNA 손상에 
대한 반응 작용으로 발현량이 매우 높게 올라간 것을 관찰할 수 있었다. 
그리고 focus 형성에 기여하는 인자로 생각되는 TGF- 유전자들이 
Non-focus군에서 발현이 떨어진 것을 관찰할 수 있었다. 게다가 DNA 
회복 시스템 관련 유전자로 알려진 Atm, Atr, Brca1, Brca2, 그리고 
Chek1 유전자들의 발현이 Focus군에서 매우 높게 올라간 것을 알 수 
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있었다. DNA 회복 시스템이 Focus군에서 전반적으로 많이 올라갔지만 
특히, error-prone DNA 회복 시스템이 Focus군에서 높게 올라간 것을 
볼 수 있었다. 세포가 외부 자극에 의해 손상을 입었을 경우, error-
free 시스템이 먼저 작동을 하고 error-free 시스템이 과부하가 되었을 
경우 error-prone 시스템이 가동이 된다. 본 연구 결과에서도 error-
prone 시스템이 올라간 것을 관찰할 수 있었는데 error-prone 시스템
에 의해 손상된 DNA가 회복이 되어 결국 제대로 회복이 되지 않고 마
침내 focus를 형성하는 것으로 생각이 된다. Focus 형성에 따른 유전체 
변화는 뚜렷하지 않았으나 전사체의 변화는 매우 극명하게 나타나는 것
을 유전자 발현 패턴 변화 연구를 통해 알 수 있었다. 이는 암 유전체 
진화적인 관점에서 볼 때, 유전체의 변화에 앞서 전사체의 변화가 1차적
으로 먼저 일어나는 경우도 있다는 것을 시사한다. 마지막으로 선행연구 
중 종양 발생과 줄기세포가 밀접한 연관이 있다는 보고가 있었다. 이를 
바탕으로 Focus가 stem cell-like 성질이 있는지를 관찰하였고 그 결과, 
Focus는 stemness가 있는 것을 확인하였다. 또한 up-regulated된 
Myc 유전자가 세포를 reprogramming 할 수 있다는 보고가 있었으며 
Myc으로 유도된 종양은 유전체의 변화가 크게 없다고 하였다. Focus는 
Myc의 발현이 올라가 있었으며 유전체의 변화 역시 크지 않았음으로 
그 결과가 선행연구와 일치한다. 본 연구의 결과를 종합해보면 Little이 
제시한 two-step 형질전환 이론에서 두 번째 단계에 관여하는 인자는 
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두 가지가 있는데 첫 번째로는 Tgf 유전자의 발현이 떨어지는 것이고 
두 번째로는 올라간 error-prone DNA 회복 시스템이다. 아주 이른 시
기의 종양 세포에서처럼 Non-focus군에서 Tgf 유전자의 발현이 떨어
짐으로써 Non-focus 세포가 Focus 세포로 형질전환이 일어나는 것에 
기여를 하였고 error-prone DNA 회복 시스템이 가동됨에 의해 제대로 
복구 되지 않은 세포들이 누적이 되어 결국 focus를 형성하였다. 그리고 
마지막으로 Focus가 갖고 있는 stem cell-like 성질과 Myc으로 유도된 
oncogenic reprogramming으로 인해 transformed cell인 Focus가 
malignancy를 갖게 된다고 생각할 수 있다. 따라서 Little의 two-step 
형질전환 이론을 정확히 밝혀냄으로써 본 연구를 통해 종양 발생에 대한 
이해도가 높아질 것으로 예상된다.  
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